drugset
drugset / Trial / NCT04845321

VNRX-9945 Safety and Pharmacokinetics in Healthy Adult Volunteers

NCT04845321 ↗

Phase 1 Terminated 32 enrolled Venatorx Pharmaceuticals, Inc. Novotech (Australia) Pty Limited · collab
RandomizedSingle-groupDouble-blindBasic science

Summary

This is a 2-part first-in-human dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-9945.

Timeline

Start
2021-06-23
Primary completion
2021-10-31
Completion
2021-10-31

Outcome

Outcome not reported

Stopped: “Part 2 terminated, unrelated to safety.”

Drugs

EvaluationDrugModalityDoseRoute
Subject VNRX-9945 Unknown — Oral

Indications

No indication recorded.